A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)

NCT00943761 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Vaniprevir 600 mg b.i.d.
DRUG: Vaniprevir 300 mg b.i.d.
DRUG: Pegylated interferon
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC